CD30-Targeted CAR T Cell Therapy Promising in Heavily Pretreated Hodgkin Lymphoma

Article

A phase 2 clinical trial evaluating a T-cell memory enriched anti-CD30 CAR-T is now underway.

Results of a phase 1 clinical trial investigating the safety and feasibility of a refined anti-CD30 CAR T-cell therapy are promising, demonstrating good cell persistence up to 11 months post-infusion and a good safety profile.1

The findings were presented at the 2022 European Hematology Association (EHA) Annual Meeting, June 9-17, 2022, in Vienna, Austria and virtual, by investigator Ana Carolina Caballero, of the department of hematology at the Hospital de la Santa Creu I Sant Pau in Barcelona, Spain.

A research group consisting of Caballero and her colleagues developed a novel CD30 CAR T by using a targeted epitope within the non-cleavable part of the CD30 receptor and memory stem T cells in hopes of improving engraftment, cell persistence, and antitumor activity.

Results of a preclinical study published in 2021 in Clinical & Translational Immunology2 by Carmen Alvarez-Fernandez, et al, demonstrated good cell expansion ex vivo and good persistence and immunity in a mouse model of Hodgkin lymphoma, which was completely eradicated in vivo. In addition, the CAR T therapy showed greater tumor infiltration and an enhanced antitumor effect in vivo.

In this first in human, phase 1/2a dose escalation clinical trial (NCT04653649), Caballero and colleagues enrolled 11 patients (median age, 49.9 years) with relapsed/refractory Hodgkin lymphoma or CD30+ T-cell non-Hodgkin lymphoma, 10 of whom ultimately received treatment with HSP-CAR30. Primary end points were safety and to establish max tolerated dose for phase 2, with response rates among secondary end points.

Patients had received a median of 4.6 prior lines of treatment. Following leukapheresis, 3 patients received dose-level 1 (3x106 /kg), 3 received dose-level 2 (5x106 /kg), and 4 received dose-level 3 (10x106 /kg). Prior to infusion, patients with HL underwent lymphodepletion with fludarabine/bendamustine and those with T-NHL received ludarabine/cyclophosphamide. Mean HSP-CAR30 expression was 94.79±3.38% (±SD). Memory T-cell subset comprised 93.07±4.8% (±SD) in CD4+ and 91.64±4.9% (±SD) in CD8+. Peak levels of HSP-CAR30 cells were reached at a mean of 29 days post-infusion and were detectable via flow cytometry up to 11 months post-infusion.

Notably, no dose-limiting toxicities were observed and the therapy was generally well tolerated. Sixty percent of patients developed grade 1 cytokine release syndrome and 40% developed skin rash. In addition, 4 infections occurred, including a grade 4 case of pulmonary tuberculosis; grade 3 CMV pneumonia in a patient with a history of cytomegalovirus; grade 1 rhinovirus; and grade 1 COVID-19. No cases of neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. Grade 3 and 4 cytopenias included anemia (5/10), thrombopenia (3/10), neutropenia (8/10), and long-lasting cytopenias (2/10). Notably, no non-relapse mortality events occurred.

In terms of efficacy, 100% of treated participants reached objective response, with 50% of the total cohort reaching complete response (CR) and 62% of patients with HL reaching CR. Three patients (2 with T-NHL and 1 with HL) succumbed to progressive disease. One patient with HL that achieved partial response with relapse at 6 months received treatment with nivolumab to again reach partial response, and received a second infusion of HSP-CAR30 between 13-14 months after initial treatment. Follow-up data is available through 14 months, with longest CR at data cutoff at 12 months.

Based on the significant antitumor efficacy observed and the good safety profile, a phase 2 study has begun examining the safety and efficacy of dose level 2 (5x106 /kg).

For more coverage of EHA 2022, click here.

REFERENCES
1. Caballero AC, Escriba-Garcia L, Montserrat-Torres R, et al. A phase 1, first-in-human, dose-escalation clinical trial of memory-enriched CD30-CAR T-cell therapy for the treatment of relapsed or refractory Hodgkin lymphoma and CD30+ T-cell lymphoma. Presented at: European Hematology Association Annual Meeting. June 9-17, 2022; Vienna, Austria, and virtual. S257.
2. Alvarez‐Fernández C, Escribà‐Garcia L, Caballero A, et al. Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. Clin Transl Immunol. 2021;10(4). doi:10.1002/cti2.1268
Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.